San Francisco, California, United States In 2009 was created Mission Bay Capital, which is appeared as VC. The leading representative office of defined VC is situated in the San Francisco. The fund was located in North America if to be more exact in United States.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Mission Bay Capital, startups are often financed by OrbiMed, Polaris Partners, Topspin Partners. The meaningful sponsors for the fund in investment in the same round are OrbiMed, OUP (Osage University Partners), SR One. In the next rounds fund is usually obtained by OrbiMed, SR One, Morgenthaler Ventures.
Besides them, we counted 3 critical employees of this fund in our database.
The top activity for fund was in 2015. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. This Mission Bay Capital works on 12 percentage points less the average amount of lead investments comparing to the other organizations. The fund is generally included in 2-6 deals every year. The top amount of exits for fund were in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Genetics, Pharmaceutical. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Alector, Bolt Threads, Caribou Biosciences.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Adesso | Dortmund, Germany, Nordrhein-Westfalen |
| Aipu Yiyao Touzi | China, Fujian, Hunan |
| Cambridge West Ventures | California, Redwood City, United States |
| Caufield Angel Fund | - |
| CMK Capital | Beijing, Beijing, China |
| DCL Ventures, Inc. | New York, New York, United States |
| Goldmann International GmbH. | China, Gansu, Sichuan |
| Grant | - |
| gumi | Japan, Tokyo |
| Hatch Ventures | British Columbia, Canada, Vancouver |
| Lufthansa Cargo | Frankfurt, Germany, Hessen |
| Mercedes-Benz Research and Development India | Bengaluru, India, Karnataka |
| Muhua Jinxin Investment Management | - |
| Oliphans Capital | India, Maharashtra, Mumbai |
| Primera Impact | Cambridge, Massachusetts, United States |
| Southern Tier Opportunity Coalitiion | Binghamton, New York, United States |
| Spruce Capital Partners | California, San Francisco, United States |
| VisionMax Health Fund | - |
| Vocap Ventures | Atlanta, Georgia, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
QurAlis | $88M | 09 Mar 2023 | Cambridge, Massachusetts, United States | ||
Nitrome Biosciences | $7M | 02 Nov 2021 | Jackson, Mississippi, United States | ||
Alpine Roads | $75M | 22 Jul 2021 | San Francisco, California, United States | ||
Nitrome Biosciences | $38M | 22 Apr 2020 | Jackson, Mississippi, United States | ||
Glycomine | $33M | 07 Aug 2019 | San Francisco, California, United States | ||
GraphWear Technologies | $4M | 17 Apr 2018 | San Francisco, California, United States | ||
Wild Type | $3M | 30 Mar 2018 | San Francisco, California, United States | ||
ViewPoint Therapeutics | $35M | 05 Mar 2018 | San Francisco, California, United States | ||
| $62M | 13 Dec 2017 | South San Francisco, California, United States |
– Nobell Foods has secured a $75m Series B financing round.
– The round was backed by Andreessen Horowitz, Breakthrough Energy Ventures.
– Others joining this round include: Unovis, Germin8 Ventures, Fifty Years, AgFunder, Pear VC, GL Ventures, the venture capital arm of Hillhouse Group, and Mission Bay Capital.
– The company plans to launch its cheeses to the public by the end of next year.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
QurAlis | $88M | 09 Mar 2023 | Cambridge, Massachusetts, United States | ||
Nitrome Biosciences | $7M | 02 Nov 2021 | Jackson, Mississippi, United States | ||
Alpine Roads | $75M | 22 Jul 2021 | San Francisco, California, United States | ||
Nitrome Biosciences | $38M | 22 Apr 2020 | Jackson, Mississippi, United States | ||
Glycomine | $33M | 07 Aug 2019 | San Francisco, California, United States | ||
GraphWear Technologies | $4M | 17 Apr 2018 | San Francisco, California, United States | ||
Wild Type | $3M | 30 Mar 2018 | San Francisco, California, United States | ||
ViewPoint Therapeutics | $35M | 05 Mar 2018 | San Francisco, California, United States | ||
| $62M | 13 Dec 2017 | South San Francisco, California, United States |
